The future of the genetic data owned by 23andMe is uncertain as the company undergoes a court-supervised sale.

Lawmakers raised questions and concerns about the sale of genetic-testing company 23andMe during a hearing on Tuesday.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

PORTLAND, Ore. (AP) — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking ...

The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

Lawmakers want to know what will be done to make sure consumer genetic testing company 23andMe’s data will stay out of the ...

People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest ...

The states say DNA samples of about 15 million previous customers are too sensitive to allow the transaction without each ...

The bipartisan lawsuit was filed on Monday in St. Louis alongside a separate objection to the bankruptcy sale and is being ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Regeneron is willing to make a new bid for 23andMe's assets, but wants a $10 million breakup fee if Wojcicki’s bid is ...

The founder of 23andMe, Anne Wojcicki, has asked a judge to reopen an auction for the genetic testing company, saying she has ...